This is a non-interventional study using existing data including medical chart review.
Study Type
OBSERVATIONAL
Enrollment
4,083
Empagliflozin
Sodium Glucose Transporter 2 inhibitor
Dipeptidyl-peptidase 4 inhibitor
Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist
Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported. The concomitant T2D medications reported are: * Metformin * Sulfonylurea * Acarbose * Pioglitazone * Insulin * Others
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported. The reported concomitant CVD and/or chronic CKD medications are: * Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) * Statins * Low dose aspirin * Beta blockers * Diuretics * Others
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Glucagon-like peptide 1 agonist
MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903
Byala, Bulgaria
MC "Diamedical 2013" OOD, Center Nr.: 35902
Dimitrovgrad, Bulgaria
MBAL- Dobrich AD, Center Nr.: 35916
Dobrich, Bulgaria
Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904
Dupnitsa, Bulgaria
MHAT "Medline Clinic", Center Nr.: 35911
Plovdiv, Bulgaria
MC Kuchuk Parij OOD, Center Nr.: 35906
Plovdiv, Bulgaria
MC Saint Elisaveta-Rakovski EOOD, Center Nr.: 35909
Rakovski, Bulgaria
"Medical Center-Razgrad"OOD, Center Nr.: 35910
Razgrad, Bulgaria
DCC 1 - Russe EOOD, Center Nr.: 35905
Rousse, Bulgaria
MBAL "Hadzhi Dimitar" OOD, Center Nr.: 35915
Sliven, Bulgaria
...and 167 more locations
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of gender are: * Female * Male
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of race are: * Black * Non-black
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of gender are: * Female * Male
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of race are: * Black * Non-black
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of gender are: * Female * Male
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of race are: * Black * Non-black
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of percentage (%) of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Any Type of Cardiovascular Disease (CVD)
Number of patients with cardiovascular disease (CVD) is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment
Number of patients with chronic kidney disease (CKD) by physician's assessment (patients for whom CKD was reported as a comorbidity) is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status
Number of patients with documentation of estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) status is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status
Number of patients with Chronic Kidney Disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Number of patients in each category of the different types of cardiovascular disease is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography
Number of patients in each category of the different types of congestive heart failure (CHF) which was confirmed by echocardiography is reported. The reported categories of congestive heart failure confirmed by echocardiography are: * Yes * No * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist
Number of patients with any type of cardiovascular disease (CVD) or without CVD according to prescribing specialist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist
Number of patients with chronic kidney (CKD) and without CKD by physician's assessment according to prescribing specialist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist
Number of patients with chronic kidney disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status - according to prescribing specialist is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients in each category of different types of cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients in each category of congestive heart failure (CHF) confirmed by echocardiography according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) or without CKD by physician's assessment according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) and without CKD by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of employment status are: * Employed * Not employed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients in each category of family status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Time frame: At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of status of T2D medication are: * Discontinued * Continued
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication by country is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
Number of patients for each type of physician specialties involved in decision for T2D therapy discontinuation according to prescribing specialist is reported.
Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication
Time to discontinuation of type 2 diabetes (T2D) treatment according to study medication is reported. Time to discontinuation of T2D medication was estimated by Kaplan-Meier analysis. Patients who did not discontinue study medication at study index date 2 were censored.
Time frame: From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..